Correlation Between Inovio Pharmaceuticals and Cytodyn
Can any of the company-specific risk be diversified away by investing in both Inovio Pharmaceuticals and Cytodyn at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inovio Pharmaceuticals and Cytodyn into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inovio Pharmaceuticals and Cytodyn, you can compare the effects of market volatilities on Inovio Pharmaceuticals and Cytodyn and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inovio Pharmaceuticals with a short position of Cytodyn. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inovio Pharmaceuticals and Cytodyn.
Diversification Opportunities for Inovio Pharmaceuticals and Cytodyn
0.8 | Correlation Coefficient |
Very poor diversification
The 3 months correlation between Inovio and Cytodyn is 0.8. Overlapping area represents the amount of risk that can be diversified away by holding Inovio Pharmaceuticals and Cytodyn in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cytodyn and Inovio Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inovio Pharmaceuticals are associated (or correlated) with Cytodyn. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cytodyn has no effect on the direction of Inovio Pharmaceuticals i.e., Inovio Pharmaceuticals and Cytodyn go up and down completely randomly.
Pair Corralation between Inovio Pharmaceuticals and Cytodyn
Considering the 90-day investment horizon Inovio Pharmaceuticals is expected to under-perform the Cytodyn. But the stock apears to be less risky and, when comparing its historical volatility, Inovio Pharmaceuticals is 1.39 times less risky than Cytodyn. The stock trades about -0.21 of its potential returns per unit of risk. The Cytodyn is currently generating about -0.09 of returns per unit of risk over similar time horizon. If you would invest 15.00 in Cytodyn on September 11, 2024 and sell it today you would lose (4.00) from holding Cytodyn or give up 26.67% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Strong |
Accuracy | 100.0% |
Values | Daily Returns |
Inovio Pharmaceuticals vs. Cytodyn
Performance |
Timeline |
Inovio Pharmaceuticals |
Cytodyn |
Inovio Pharmaceuticals and Cytodyn Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Inovio Pharmaceuticals and Cytodyn
The main advantage of trading using opposite Inovio Pharmaceuticals and Cytodyn positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inovio Pharmaceuticals position performs unexpectedly, Cytodyn can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytodyn will offset losses from the drop in Cytodyn's long position.Inovio Pharmaceuticals vs. Novavax | Inovio Pharmaceuticals vs. Vaxart Inc | Inovio Pharmaceuticals vs. Enveric Biosciences | Inovio Pharmaceuticals vs. Ocean Biomedical |
Cytodyn vs. Madrigal Pharmaceuticals | Cytodyn vs. Scpharmaceuticals | Cytodyn vs. Akero Therapeutics | Cytodyn vs. Cardiff Oncology |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Complementary Tools
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Stocks Directory Find actively traded stocks across global markets |